Nicotinamide and methionine reduce the liver toxic effect of methotrexate.

@article{Krger1999NicotinamideAM,
  title={Nicotinamide and methionine reduce the liver toxic effect of methotrexate.},
  author={Hans Kr{\"o}ger and Annette Hauschild and Manuela Ohde and Karl Bache and Wolf P. Voigt and W Thefeldt and D. Kr{\"u}ger},
  journal={General pharmacology},
  year={1999},
  volume={33 2},
  pages={
          203-6
        }
}

Effect of Methotrexate on the Liver Enzymes and Lipid Profile in Adult Female Albino Mice

The evaluation of the effects of MTX on some liver enzymes and lipid profile was studied and a significant (p<0.05) increase in serum levels of glutamic oxaloacetate transaminase (GOT) , glutamic pyruric transaminases (GPT), Alkaline phosphatase (ALP) , total cholesterol and triglyceride (TG), however high density lipoprotein (HDL) showed a significant decrease in mice treated by MTX.

Prevention of methotrexate-induced nephrotoxicity by concomitant administration of garlic aqueous extract in rat.

Pretreatment with garlic significantly improved renal function and increased renal antioxidant enzyme activities and reduced renal oxidative stress and prevented alterations in renal morphology.

Protective Role of Vitamin E on Methotrexate Induced Renal Injury in Rabbits

Findings suggest that vitamin E, by improving cellular anti-oxidant defense system, reduction in lipid peroxidation production and tissue damage, appears to have a protective role in the MTX-induced oxidative injury in renal tissue.

Protective effect of pentoxyfilline in renal toxicity after methotrexate administration.

The increased level of tissue MDA and serum TNF-alpha level together may be suggested that the underlying mechanism is related to direct toxicity of MTX rather than blockage in folate synthesis in kidneys.

Efficiency of combined methotrexate/chloroquine therapy in adjuvant‐induced arthritis

It is suggested that combined methotrexate and chloroquine treatment provides more effective anti‐inflammatory protection against adjuvant‐induced arthritis than does MTX alone, reverting the alterations in enzyme activities induced by this inflammatory disease in rats.

Nicotinamide Phosphoribosyltransferase Attenuates Methotrexate Response in Juvenile Idiopathic Arthritis and In Vitro

Evidence is provided that NAMPT inhibits the pharmacological activity of MTX and may represent a predictive biomarker of response, as well as a therapeutic target, in the treatment of JIA with MTX.

The activities of purine-catabolizing enzymes and the level of nitric oxide in rat kidneys subjected to methotrexate: Protective effect of caffeic acid phenethyl ester

It is revealed that NO, XO and ADA may play an important role in the pathogenesis ofMTX-induced oxidative renal damage and CAPE may have protective potential in this process and it will become a promising drug in the prevention of this undesired side effect of MTX.

The effect of alpha lipoic acid on rat kidneys in methotrexate induced oxidative injury.

MTX made oxidative damage on kidneys of rat and it was partially prevented by anti-inflammatory and antioxidant effects of ALA treatment, as well as histopathological alterations induced by MTX administration.

Effect of methionine on hepatotoxicity due to co-administration of gentamicin and indomethacin in rats

Results revealed that gentamicin may aggravate indomethacin hepatotoxicity, and methionine managed to ameliorate this effect.

Methotrexate-induced renal oxidative stress in rats: the role of a novel antioxidant caffeic acid phenethyl ester

Investigation of the role of caffeic acid phenethyl ester (Caffeic Ester), a novel antioxidant, on methotrexate-induced renal oxidative stress in rats found that it leads to a reduction in antioxidant enzymatic defense capacity and causes lipid peroxidation in renal tissue.

References

SHOWING 1-10 OF 14 REFERENCES

The use of methotrexate in steroid-resistant systemic lupus erythematosus.

Improvements in the response to MTX in patients with steroid-resistant SLE in an open, unblinded study suggest that controlled studies of MTX for the treatment of SLE are justified.

Second-line drug therapy for rheumatoid arthritis.

Three major classes of drugs are used in the treatment of patients with rheumatoid arthritis: nonsteroidal antiinflammatory drugs, corticosteroids, and drugs that are thought to modify fundamental

Long-term methotrexate therapy for rheumatoid arthritis.

Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate.

The results indicate that in hospital clinic patients with RA pneumonitis is a common adverse reaction to Methotrexate therapy, and suggest that hypersensitivity is probably responsible for most cases of pneum onitis associated with MTX, but preexisting lung disease may confer increased risk.

Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months.

It is concluded that a majority of rheumatoid arthritis patients are able to continue MTX treatment with generally sustained efficacy, for intervals that meaningfully exceed those reported previously.

Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone.

Estimated drug continuation did not differ significantly according to age, duration of disease, or whether the drug was the first, second, or 3rd 2nd line drug used, but most courses were not continued beyond 2 years.